Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant987 active trials8 approved drugs63 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,216 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT06196658 | Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer | not yet recruiting | Early Phase 1 | 6 | Zhang Xiaofeng,MDOTHER | 0 | Jan 9, 2024 | clinicaltrials |
| Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer |
| withdrawn |
| Early Phase 1 |
| 0 |
| Roswell Park Cancer InstituteOTHER |
| 1 |
| Dec 22, 2023 |
| clinicaltrials |
| NCT05465590 | A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer | withdrawn | Early Phase 1 | 0 | Mainline Biosciences, Inc.INDUSTRY | 0 | Dec 21, 2023 | clinicaltrials |
| NCT06156267 | Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino | not yet recruiting | Early Phase 1 | 30 | Fudan UniversityOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT05916261 | Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer | recruiting | Early Phase 1 | 54 | Ruijin HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06054984 | TCR-T Cells in the Treatment of Advanced Pancreatic Cancer(GB3010-02) | unknown | Early Phase 1 | 18 | Ruijin HospitalOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT02683824 | Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers | completed | Early Phase 1 | 21 | Stanford UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05886075 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors | unknown | Early Phase 1 | 24 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05875753 | 68Ga-FAPI-FS PET/CT and PET/MR in Pancreatic Cancer | unknown | Early Phase 1 | 50 | Peking Union Medical College HospitalOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT05860374 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT05583201 | NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors | unknown | Early Phase 1 | 18 | jianming xuOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05034783 | [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients | unknown | Early Phase 1 | 20 | Peking Union Medical College HospitalOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT05438797 | The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer | unknown | Early Phase 1 | 3 | Sizhen WangOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT01371240 | Secretin-Assisted Computed Tomography Scan and Magnetic Resonance Imaging in Improving Pancreatic Tumor Conspicuity | withdrawn | Early Phase 1 | 0 | University Hospitals Cleveland Medical CenterOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT05275062 | Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma | unknown | Early Phase 1 | 6 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Mar 11, 2022 | clinicaltrials |
| NCT04966143 | Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer | unknown | Early Phase 1 | 30 | Shanghai Longyao Biotechnology Inc., Ltd.OTHER | 1 | Jul 19, 2021 | clinicaltrials |
| NCT02550327 | Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer | completed | Early Phase 1 | 20 | Baylor Research InstituteOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT03536208 | Biological Effect of Warfarin on Pancreatic Cancer | withdrawn | Early Phase 1 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 25, 2021 | clinicaltrials |
| NCT03718650 | Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer | withdrawn | Early Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT03600623 | Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer | terminated | Early Phase 1 | 25 | University of Alabama at BirminghamOTHER | 1 | Aug 18, 2020 | clinicaltrials |
| NCT03890198 | A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma | terminated | Early Phase 1 | 2 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jul 2, 2020 | clinicaltrials |
| NCT02153450 | Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer | completed | Early Phase 1 | 8 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 26, 2020 | clinicaltrials |
| NCT04185350 | Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma | unknown | Early Phase 1 | 60 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Dec 4, 2019 | clinicaltrials |
| NCT00414570 | An Imaging Study of [18]F-fluoro-3'-Deoxy-3'-L-fluorothymidine ([18]F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine or Other Nucleoside Analogs | terminated | Early Phase 1 | 11 | AHS Cancer Control AlbertaOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03481920 | A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer | terminated | Early Phase 1 | 7 | PH Research, S.L.OTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT01992705 | Borderline Pancreas Study: FOLFIRINOX +SBRT(GCC 1324) | completed | Early Phase 1 | 8 | University of Maryland, BaltimoreOTHER | 1 | Aug 19, 2019 | clinicaltrials |
| NCT02295956 | Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer | completed | Early Phase 1 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2019 | clinicaltrials |
| NCT01276613 | Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas | terminated | Early Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT00364364 | Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer. | terminated | Early Phase 1 | 2 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT02847000 | p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer | completed | Early Phase 1 | 13 | Yogen SaunthararajahOTHER | 1 | Jan 9, 2019 | clinicaltrials |
| NCT00867126 | Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine | terminated | Early Phase 1 | 6 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 26, 2018 | clinicaltrials |
| NCT02442739 | Ketamine for Preventing Depression in Patients Undergoing Treatment for Pancreatic or Head and Neck Cancers | withdrawn | Early Phase 1 | 0 | Cedars-Sinai Medical CenterOTHER | 1 | Nov 6, 2018 | clinicaltrials |
| NCT03497819 | Autologous CARTmeso/19 Against Pancreatic Cancer | unknown | Early Phase 1 | 10 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Apr 13, 2018 | clinicaltrials |
| NCT03267173 | Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. | unknown | Early Phase 1 | 10 | First Affiliated Hospital of Harbin Medical UniversityOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT02929797 | Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer(AKT) | unknown | Early Phase 1 | 72 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 11, 2016 | clinicaltrials |
| NCT01962909 | Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer | terminated | Early Phase 1 | 3 | University of VirginiaOTHER | 1 | Mar 18, 2016 | clinicaltrials |
| NCT02707315 | A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer | unknown | Early Phase 1 | 15 | The Cooper Health SystemOTHER | 1 | Mar 14, 2016 | clinicaltrials |
| NCT02560376 | 68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | Sep 25, 2015 | clinicaltrials |
| NCT01694589 | A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer | withdrawn | Early Phase 1 | 0 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 12, 2014 | clinicaltrials |
| NCT02024997 | Improving Pancreas Radiotherapy Plans Using Respiration-driven Anatomic Deformation: A Pilot Study | completed | Early Phase 1 | 15 | Cedars-Sinai Medical CenterOTHER | 1 | Oct 30, 2014 | clinicaltrials |
| NCT00427752 | Abdominal Exploration Without Incisions | completed | Early Phase 1 | 20 | Jeffrey HazeyOTHER | 1 | May 7, 2012 | clinicaltrials |
| NCT00436410 | Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer | completed | Early Phase 1 | 108 | National Institutes of Health Clinical Center (CC)NIH | 1 | May 2, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Jan 23, 2024source: clinicaltrials